Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

We came across a bullish thesis on AbbVie Inc. (ABBV) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we ...

The ocular hypertension market is growing due to the rising prevalence of conditions impairing aqueous humor outflow, such as scarring and inflammation, leading to elevated intraocular pressure (IOP).

Japanese drugmaker Sumitomo Pharma Company has concluded a co-promotion collaboration partner agreement with US healthcare ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.